Bioprocessing Market Report By Insights, Size, and Growth

The bioprocessing market is anticipated to experience significant growth, with projections indicating an increase from US$ 25.35 billion in 2023 to US$ 75.55 billion by 2031. This growth trajectory suggests a compound annual growth rate (CAGR) of 14.0% from 2023 to 2031. The rise in chronic disease prevalence and the expanding biopharmaceutical sector are key factors driving this market expansion.

Bioprocessing involves enhancing the quantity of living cells or biological systems/components, such as bacteria, enzymes, proteins, viruses, or nucleic acids, within a commercial bioreactor for the production of biopharmaceuticals. The products generated in this sector are typically high-quality therapeutics and vaccines that are essential for the advancement of modern healthcare. The current landscape of the bioprocessing industry is marked by rapid developments, fueled by advancements in biotechnology and a rising demand for biopharmaceuticals. This demand surge is largely due to the increasing incidence of chronic diseases, the growing trend towards personalized medicine, and the expanding applications of bioprocessing across various sectors. As bioprocessing plays a crucial role in the production of therapeutic proteins, vaccines, and other bio-based products, it has become a pivotal element in the biotechnological revolution. The market is evolving to meet the needs of a transforming healthcare environment, with a focus on efficient and scalable bioproduction processes expected to introduce new trends in the bioprocessing market in the years ahead.

Growth of the Biopharmaceutical Sector Fuels Bioprocessing Market

The biopharmaceutical industry consistently seeks improved bioprocesses to comply with new regulatory standards, quality control measures, and production challenges associated with biological products, cell culture titration, and biosimilar production. Recently, the biopharmaceutical sector has been expanding at an extraordinary rate. Companies in this field are investing heavily in research and development to create new molecules with enhanced therapeutic and commercial efficacy for a variety of medical applications. The acceptance of bioprocessing is on the rise due to its extensive use in the research, development, and manufacturing of biologics and biosimilars. Major pharmaceutical companies and contract research organizations are innovating new medicines and therapies to address a wide array of health conditions. Additionally, the strong demand for biologics and biosimilars aimed at treating chronic diseases is further propelling the growth of the biopharmaceutical industry. This sector is a significant contributor to the economy, with the United States being the largest market for biopharmaceuticals and a leader in biopharmaceutical research and development. According to the Pharmaceutical Research and Manufacturers Association, U.S. companies conduct over half of the global pharmaceutical R&D, amounting to US$ 75 billion, and hold the most patents for new medications. Emerging economies like Brazil, China, and India are also witnessing rapid growth in their research environments. Factors such as increasing approvals for biologics, a growing pipeline of biosimilars, rising investments in research, and a focus on developing affordable biologics are driving the biopharmaceutical industry's expansion.

Moreover, the increasing approvals for gene and cell therapies are contributing positively to the growth of the bioprocessing market. Notable approved gene therapies include Glybera, which treats lipoprotein lipase deficiency, and Strimvelis, aimed at treating ADA-severe combined immunodeficiency. These developments are driving the demand for large-scale production of various therapeutics, thereby facilitating the global growth of the bioprocessing market.

Market Trends

Transition to Automated Cell Therapy Manufacturing

The rise in cell therapies has transitioned the production of these products from small-scale to large-scale operations globally. Increased research in cell therapies has heightened the demand for advanced manufacturing solutions. Consequently, numerous companies are developing products to cater to the needs of academic researchers and large biotechnology firms. For example, the Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are designed to automate most sequential unit operations for CAR-T processes within a single system. Furthermore, the evolution of cell therapy from academic and clinical settings to mass production and commercialization is driving the need for automation in manufacturing. In May 2019, GE Healthcare introduced the Chronicle web application to support the entire cell therapy workflow. This automation software is compliant with good manufacturing practices and aims to optimize complex cell therapy process development and manufacturing. Companies are also engaging in strategic partnerships to enhance automation in cell therapy. For instance, in July 2020, Thermo Fisher Scientific Inc. collaborated with Lyell Immunopharma to develop and manufacture processes for effective cell therapies for cancer patients. This partnership aims to improve T-cell fitness and create an integrated cGMP-compliant platform, including systems, software, reagents, consumables, and instruments. In March 2019, Lonza partnered with Sheba Medical Center in Israel to provide automated and closed CAR-T manufacturing using its Cocoon cell therapy manufacturing platform.

Automated processes can significantly lower production costs while improving staff productivity and retention rates. Additionally, automation minimizes potential contamination sources in manufacturing environments, enhancing process consistency and resulting in higher quality products by reducing manual errors. Therefore, the growing adoption of automation among cell therapy manufacturers, along with ongoing product innovations in cell therapy, is expected to drive the bioprocessing or manufacturing of cell therapies.

The "Global Bioprocessing Market" is categorized based on product, scale of operation, process, application, end user, and geography.

Product-Based Insights

The bioprocessing market is divided into instruments and consumables/accessories. The instruments segment held a larger market share in 2023 and is projected to achieve a higher CAGR of 14.5% during the forecast period. This segment includes chromatography systems, filtration devices, osmometers, incubators, centrifuges, drying devices, and bioreactors. Chromatography systems are designed to deliver consistent performance with processing flexibility tailored to client needs, from pilot to process scale. Sartorius AG offers the Resolute BioSC Pilot Multi-Column Chromatography Systems, which are configurable automated systems that provide comprehensive support in pre- and post-sales. Recent advancements in bioreactor designs have led to sophisticated systems capable of accommodating various cell types, including mammalian, microbial, plant, and insect cells. The adoption of single-use and flexible bioreactor technologies has gained traction, offering scalability, flexibility, and reduced contamination risks. Innovations in filtration technologies have resulted in advanced filter media, such as depth filters, membrane filters, and chromatographic resins, which enhance capture efficiency, scalability, and purity for bioprocessing applications.

Process-Based Insights

The bioprocessing market is also segmented into downstream and upstream processes. The downstream bioprocess segment dominated the market share in 2023 and is expected to register a higher CAGR of 14.4% during the forecast period. The upstream bioprocess accounted for 31.2% of the market share. Upstream bioprocessing is crucial for the success of the product, as it lays the groundwork for the quality and quantity of the final product. This phase involves the initial stages of production, where microbes, cells, and bacteria are cultivated and developed through various technologies and media. These stages are complex and require stringent control over cell cultures and their growth environments. Key stages in upstream bioprocessing include cell isolation, cultivation, cell banking, and culture expansion. Furthermore, technologies such as artificial intelligence and machine learning are anticipated to play a vital role in enhancing upstream bioprocessing efficiency.

Sources such as the US Food and Drug Administration, Global Cancer Observatory, World Health Organization, Organization for Economic Co-operation and Development, National Human Genome Research Institute, International Trade Administration, and Pharmaceutical Research and Manufacturers Association have been referenced in the preparation of this bioprocessing market research report.

Bioprocessing Market Report By Insights, Size, and Growth - 2031

Growth of the Biopharmaceutical Sector Fuels Bioprocessing Market

Market Trends

Transition to Automated Cell Therapy Manufacturing

Product-Based Insights

Process-Based Insights

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

Related Reports